Valproat-Formulierungen mit gesteuerter Freigabe

Valproat-Formulierungen mit gesteuerter Freigabe

An oral controlled release composition, including a valproate compound, suitable for once-a-day administration characterized in that when said composition is ingested orally, said composition produces a valproate Cmax that is statistically significantly lower than the valproate Cmax produced by a de...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Hauptverfasser: BOLLINGER, DANIEL J, SOMMERVILLE, KENNETH W, CHESKIN, HOWARD S, QIU, YIHONG, POSKA, RICHARD P, ENGH, KEVIN R, DUTTA, SANDEEP
Format: Patent
Sprache:ger
Schlagworte:
HUMAN NECESSITIES
HYGIENE
MEDICAL OR VETERINARY SCIENCE
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS
Online-Zugang:Volltext bestellen
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page
container_issue
container_start_page
container_title
container_volume
creator BOLLINGER, DANIEL J
SOMMERVILLE, KENNETH W
CHESKIN, HOWARD S
QIU, YIHONG
POSKA, RICHARD P
ENGH, KEVIN R
DUTTA, SANDEEP
description An oral controlled release composition, including a valproate compound, suitable for once-a-day administration characterized in that when said composition is ingested orally, said composition produces a valproate Cmax that is statistically significantly lower than the valproate Cmax produced by a delayed release divalproex sodium tablet, when each is determined at steady state in a fasting population. This composition minimizes the variation between peak and trough plasma levels of valproate over a 24 hour dosing period. This composition follows a zero-order release pattern thus producing essentially flat plasma levels of valproate, once steady-state levels have been achieved. This results in a significantly lower incidence of side effects for patients consuming such a composition.
format Patent
fullrecord <record><control><sourceid>epo_EVB</sourceid><recordid>TN_cdi_epo_espacenet_DE60105381TT2</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>DE60105381TT2</sourcerecordid><originalsourceid>FETCH-epo_espacenet_DE60105381TT23</originalsourceid><addsrcrecordid>eNrjZDAIS8wpKMpPLNF1yy_KLc3JTC0qzUtPzVPIzSxRSE8tLkktTS0qSS1ScCtKzUxPTErlYWBNS8wpTuWF0twMSm6uIc4euqkF-fGpxQWJyal5qSXxLq5mBoYGpsYWhiEhRsZEKQIA-g4sgQ</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>patent</recordtype></control><display><type>patent</type><title>Valproat-Formulierungen mit gesteuerter Freigabe</title><source>esp@cenet</source><creator>BOLLINGER, DANIEL J ; SOMMERVILLE, KENNETH W ; CHESKIN, HOWARD S ; QIU, YIHONG ; POSKA, RICHARD P ; ENGH, KEVIN R ; DUTTA, SANDEEP</creator><creatorcontrib>BOLLINGER, DANIEL J ; SOMMERVILLE, KENNETH W ; CHESKIN, HOWARD S ; QIU, YIHONG ; POSKA, RICHARD P ; ENGH, KEVIN R ; DUTTA, SANDEEP</creatorcontrib><description>An oral controlled release composition, including a valproate compound, suitable for once-a-day administration characterized in that when said composition is ingested orally, said composition produces a valproate Cmax that is statistically significantly lower than the valproate Cmax produced by a delayed release divalproex sodium tablet, when each is determined at steady state in a fasting population. This composition minimizes the variation between peak and trough plasma levels of valproate over a 24 hour dosing period. This composition follows a zero-order release pattern thus producing essentially flat plasma levels of valproate, once steady-state levels have been achieved. This results in a significantly lower incidence of side effects for patients consuming such a composition.</description><edition>7</edition><language>ger</language><subject>HUMAN NECESSITIES ; HYGIENE ; MEDICAL OR VETERINARY SCIENCE ; PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES ; SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS</subject><creationdate>2005</creationdate><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://worldwide.espacenet.com/publicationDetails/biblio?FT=D&amp;date=20050929&amp;DB=EPODOC&amp;CC=DE&amp;NR=60105381T2$$EHTML$$P50$$Gepo$$Hfree_for_read</linktohtml><link.rule.ids>230,308,776,881,25542,76289</link.rule.ids><linktorsrc>$$Uhttps://worldwide.espacenet.com/publicationDetails/biblio?FT=D&amp;date=20050929&amp;DB=EPODOC&amp;CC=DE&amp;NR=60105381T2$$EView_record_in_European_Patent_Office$$FView_record_in_$$GEuropean_Patent_Office$$Hfree_for_read</linktorsrc></links><search><creatorcontrib>BOLLINGER, DANIEL J</creatorcontrib><creatorcontrib>SOMMERVILLE, KENNETH W</creatorcontrib><creatorcontrib>CHESKIN, HOWARD S</creatorcontrib><creatorcontrib>QIU, YIHONG</creatorcontrib><creatorcontrib>POSKA, RICHARD P</creatorcontrib><creatorcontrib>ENGH, KEVIN R</creatorcontrib><creatorcontrib>DUTTA, SANDEEP</creatorcontrib><title>Valproat-Formulierungen mit gesteuerter Freigabe</title><description>An oral controlled release composition, including a valproate compound, suitable for once-a-day administration characterized in that when said composition is ingested orally, said composition produces a valproate Cmax that is statistically significantly lower than the valproate Cmax produced by a delayed release divalproex sodium tablet, when each is determined at steady state in a fasting population. This composition minimizes the variation between peak and trough plasma levels of valproate over a 24 hour dosing period. This composition follows a zero-order release pattern thus producing essentially flat plasma levels of valproate, once steady-state levels have been achieved. This results in a significantly lower incidence of side effects for patients consuming such a composition.</description><subject>HUMAN NECESSITIES</subject><subject>HYGIENE</subject><subject>MEDICAL OR VETERINARY SCIENCE</subject><subject>PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES</subject><subject>SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS</subject><fulltext>true</fulltext><rsrctype>patent</rsrctype><creationdate>2005</creationdate><recordtype>patent</recordtype><sourceid>EVB</sourceid><recordid>eNrjZDAIS8wpKMpPLNF1yy_KLc3JTC0qzUtPzVPIzSxRSE8tLkktTS0qSS1ScCtKzUxPTErlYWBNS8wpTuWF0twMSm6uIc4euqkF-fGpxQWJyal5qSXxLq5mBoYGpsYWhiEhRsZEKQIA-g4sgQ</recordid><startdate>20050929</startdate><enddate>20050929</enddate><creator>BOLLINGER, DANIEL J</creator><creator>SOMMERVILLE, KENNETH W</creator><creator>CHESKIN, HOWARD S</creator><creator>QIU, YIHONG</creator><creator>POSKA, RICHARD P</creator><creator>ENGH, KEVIN R</creator><creator>DUTTA, SANDEEP</creator><scope>EVB</scope></search><sort><creationdate>20050929</creationdate><title>Valproat-Formulierungen mit gesteuerter Freigabe</title><author>BOLLINGER, DANIEL J ; SOMMERVILLE, KENNETH W ; CHESKIN, HOWARD S ; QIU, YIHONG ; POSKA, RICHARD P ; ENGH, KEVIN R ; DUTTA, SANDEEP</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-epo_espacenet_DE60105381TT23</frbrgroupid><rsrctype>patents</rsrctype><prefilter>patents</prefilter><language>ger</language><creationdate>2005</creationdate><topic>HUMAN NECESSITIES</topic><topic>HYGIENE</topic><topic>MEDICAL OR VETERINARY SCIENCE</topic><topic>PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES</topic><topic>SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS</topic><toplevel>online_resources</toplevel><creatorcontrib>BOLLINGER, DANIEL J</creatorcontrib><creatorcontrib>SOMMERVILLE, KENNETH W</creatorcontrib><creatorcontrib>CHESKIN, HOWARD S</creatorcontrib><creatorcontrib>QIU, YIHONG</creatorcontrib><creatorcontrib>POSKA, RICHARD P</creatorcontrib><creatorcontrib>ENGH, KEVIN R</creatorcontrib><creatorcontrib>DUTTA, SANDEEP</creatorcontrib><collection>esp@cenet</collection></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext_linktorsrc</fulltext></delivery><addata><au>BOLLINGER, DANIEL J</au><au>SOMMERVILLE, KENNETH W</au><au>CHESKIN, HOWARD S</au><au>QIU, YIHONG</au><au>POSKA, RICHARD P</au><au>ENGH, KEVIN R</au><au>DUTTA, SANDEEP</au><format>patent</format><genre>patent</genre><ristype>GEN</ristype><title>Valproat-Formulierungen mit gesteuerter Freigabe</title><date>2005-09-29</date><risdate>2005</risdate><abstract>An oral controlled release composition, including a valproate compound, suitable for once-a-day administration characterized in that when said composition is ingested orally, said composition produces a valproate Cmax that is statistically significantly lower than the valproate Cmax produced by a delayed release divalproex sodium tablet, when each is determined at steady state in a fasting population. This composition minimizes the variation between peak and trough plasma levels of valproate over a 24 hour dosing period. This composition follows a zero-order release pattern thus producing essentially flat plasma levels of valproate, once steady-state levels have been achieved. This results in a significantly lower incidence of side effects for patients consuming such a composition.</abstract><edition>7</edition><oa>free_for_read</oa></addata></record>
fulltext fulltext_linktorsrc
identifier
ispartof
issn
language ger
recordid cdi_epo_espacenet_DE60105381TT2
source esp@cenet
subjects HUMAN NECESSITIES
HYGIENE
MEDICAL OR VETERINARY SCIENCE
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS
title Valproat-Formulierungen mit gesteuerter Freigabe
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-08T03%3A23%3A55IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-epo_EVB&rft_val_fmt=info:ofi/fmt:kev:mtx:patent&rft.genre=patent&rft.au=BOLLINGER,%20DANIEL%20J&rft.date=2005-09-29&rft_id=info:doi/&rft_dat=%3Cepo_EVB%3EDE60105381TT2%3C/epo_EVB%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/&rfr_iscdi=true